Gynecologic Oncology | Specialty

Strategies Emerging for PARP Inhibitor Resistance in Ovarian Cancer

August 28th 2019

Kathleen Moore, MD, combs through the various investigational strategies exploring management of resistance to PARP inhibitors in ovarian cancer.

Hope Is Not Lost on Hunt for Effective Ovarian Cancer Screening Test

August 28th 2019

Laura L. Holman, MD, discusses ongoing efforts in ovarian cancer screening and what may lie ahead for generations to come.

Prolonging PFS With PARP Inhibitors in Platinum-Sensitive Ovarian Cancer

August 22nd 2019

Alexander Olawaiye, MD, discusses the trials that led to the expanded approvals of PARP inhibitors as maintenance therapy in women with platinum-sensitive ovarian cancer.

Frontline Data for Newly Diagnosed Ovarian Cancer Leave Much to Be Discerned

August 22nd 2019

Jessica L. Berger, MD, evaluates the treatment approaches available for patients with newly diagnosed advanced ovarian cancer.

Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian Cancer

August 22nd 2019

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, poses unanswered questions pertaining to the use and reuse of PARP inhibitors in ovarian cancer treatment.

Ovarian Cancer Researchers Continue to Push the Envelope

August 21st 2019

At the 2019 OncLive® State of the Science Summit™ on Ovarian Cancer, we asked experts from the University of Pittsburgh Medical Center about the intriguing research being conducted at their institution.

Recurrent Ovarian Cancer Paradigm Continues to Evolve

August 21st 2019

Madeleine B. Courtney Brooks, MD, MPH, sheds light on the current treatment paradigm of recurrent ovarian cancer.

Immunotherapy Combo Strategies Are Major Research Focus in Ovarian Cancer

August 21st 2019

Brian Orr, MD, discusses the challenges with immunotherapy in ovarian cancer treatment while pointing to early promising data with combination regimens.

Questions Remain Across Treatment Modalities in Ovarian Cancer

August 20th 2019

John Comerci, Jr, MD, provides an overview of advances made in ovarian cancer and remaining challenges to address with future research.

PARP Inhibition Improves PFS as Frontline Maintenance in Ovarian Cancer, OS Data Awaited

August 20th 2019

Lan G. Coffman, MD, PhD, discusses pivotal trials evaluating frontline maintenance therapy in advanced ovarian cancer and unanswered questions that still need to be addressed with future research.

PARP Inhibition Continues to Make Waves in Ovarian Cancer

August 19th 2019

Terry L. Evans, MD, discusses the use of PARP inhibitors in ovarian cancer and how they are poised to optimally fit in the treatment paradigm.

Olaparib Plus Bevacizumab Improves PFS as Frontline Maintenance in Ovarian Cancer

August 14th 2019

Combining olaparib with standard bevacizumab significantly improved progression-free survival compared with bevacizumab alone as frontline maintenance therapy in women with advanced ovarian cancer, regardless of BRCA status, according to topline results from the phase III PAOLA-1 trial.

Expert Explains Intricacies of Molecular Testing in Ovarian Cancer

August 13th 2019

Sarah E. Taylor, MD, discusses the role of somatic and germline testing for patients with ovarian cancer and their family members to create more personalized treatment and prevent disease.

Neoadjuvant Chemo Shows Comparable Data to Upfront Surgery in Ovarian Cancer

August 8th 2019

Michelle M. Boisen, MD, discusses the role of neoadjuvant chemotherapy in advanced ovarian cancer and data comparing outcomes with this modality versus upfront surgery.

Harnessing Immune Response in Advanced Ovarian Cancer

August 5th 2019

Mian M. Shahzad, MD, PhD, discusses the use of checkpoint inhibition in advanced ovarian cancer.

Assessing Strategies and Challenges in Newly Diagnosed and Recurrent Ovarian Cancer

August 5th 2019

Jeannie Chern, MD, discusses developments with genetic testing in ovarian cancer and key trials in patients with recurrent disease.

Is Neoadjuvant Chemo Becoming Standard of Care for Advanced Ovarian Cancer?

August 2nd 2019

Mitchel Hoffman, MD, explains the use of surgery and neoadjuvant chemotherapy in ovarian cancer.

SOLO-1 Paves Path for Frontline Maintenance in Ovarian Cancer

August 1st 2019

Hye Sook Chon, MD, discusses the progress of maintenance therapy in ovarian cancer.

The Future of Managing Gynecologic Cancer

July 30th 2019

Standard Frontline Therapy for Endometrial Cancer

July 30th 2019